Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H21F3N2O2 |
Molecular Weight | 318.3346 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCCC\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN
InChI
InChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors. Fluvoxamine is used for management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa. Fluvoxamine is known under the brand names: Faverin, Fevarin, Floxyfral, Dumyrox and Luvox.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological profile of antidepressants and related compounds at human monoamine transporters. | 1997 Dec 11 |
|
Pharmacological characterization and visualization of the glial serotonin transporter. | 2001 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
Sample Use Guides
Usual Adult Dose for Obsessive Compulsive Disorder Initial extended release capsule dose: 100 mg orally once a day at bedtime Initial immediate release tablet dose: 50 mg orally once a day at bedtime Maintenance dose: 100 to 300 mg orally per day. The dose may be increased in 50 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved. Maximum Dose: 300 mg orally per day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175696
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
NDF-RT |
N0000000109
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
WHO-ATC |
N06AB08
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
LIVERTOX |
431
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
WHO-VATC |
QN06AB08
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
||
|
NCI_THESAURUS |
C94725
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54739-18-3
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
5324346
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
FLUVOXAMINE
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
42355
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | RxNorm | ||
|
7189
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
D016666
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
SUB07769MIG
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
C61769
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
DB00176
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
54739-18-3
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
CHEMBL814
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
M5516
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | Merck Index | ||
|
54739-18-3
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY | |||
|
3879
Created by
admin on Tue Oct 22 00:25:46 UTC 2019 , Edited by admin on Tue Oct 22 00:25:46 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)